glp3.wiki
Investigational · not FDA approved

Editorially reviewed · Last updated September 8, 2026 · How we review

Stopping Retatrutide: What Happens When You Come Off

Part of How-To Guides.

Key findings

  • No completed retatrutide withdrawal result establishes a personal regain forecast.
  • In SURMOUNT-4, the placebo-switch group gained 14.0% relative to its weight at randomization, after a 36-week tirzepatide lead-in.
  • That group remained 9.9% below its original baseline weight at week 88.
  • Retatrutide receptor count and half-life do not establish faster regain or a safe taper.
  • Stopping, maintenance and switching decisions need a clinical plan; online schedules are not trial evidence.

Stopping Retatrutide: What Happens When You Come Off

We found no completed retatrutide withdrawal trial establishing how much weight people regain after stopping. Published withdrawal evidence for tirzepatide shows that regain is common, but it cannot supply a retatrutide-specific rate or prove that retatrutide rebound is faster.

Obesity treatment often requires a long-term plan. This page separates the observed tirzepatide withdrawal results from what remains unknown about retatrutide, including tapering and switching to another treatment.

How Much Weight Comes Back: The SURMOUNT-4 Evidence

Retatrutide has no published withdrawal trial. The best available evidence is SURMOUNT-4 (JAMA 2024), a Phase 3 randomized withdrawal study of tirzepatide — the dual agonist that shares two of retatrutide's three receptor targets (GLP-1 and GIP). Participants lost a mean 20.9% of body weight over a 36-week lead-in, then were randomized either to keep taking tirzepatide or to switch to placebo for 52 more weeks.
From week 36 (randomization)Continued drugSwitched to placebo
Weight change, weeks 36–88−5.5% (kept losing)+14.0% (regained)
Difference between groups−19.4 percentage points (95% CI −21.2 to −17.7)
Maintained at least 80% of lost weight89.5%16.6%
Overall weight reduction, week 0–8825.3%9.9%
The placebo group’s 14.0% increase was measured from weight at randomization, after the initial 36-week loss—not 14% of original starting weight. At week 88, that group remained 9.9% below its original weight on average. Individual outcomes varied.

Those results establish the effect of withdrawing tirzepatide in this trial. They do not establish an “at least as severe” rebound with retatrutide.

Can We Predict Retatrutide Weight Regain?

The Phase 2 retatrutide weight-loss curve had not plateaued at 48 weeks. That describes the on-treatment trajectory; it does not measure what happens after treatment ends.

A larger treatment effect does not, by itself, establish a faster or larger rebound. The relevant evidence would compare continued treatment, withdrawal or a maintenance strategy over time. Lilly’s development program includes TRIUMPH-6, a maintenance study, but completed withdrawal results were not available in this review.

Symptoms People Report When Coming Off

Retatrutide exposure declines over days and weeks after the last dose; its approximate half-life is six days. That does not establish when appetite, pulse, GI symptoms or mood will change for an individual, and it does not guarantee that a symptom resolves within a month.

Reports of food noise returning or side effects easing are useful questions for research, but anecdotes cannot establish frequency or causation. Persistent palpitations, significant mood changes or severe GI symptoms should be assessed rather than assumed to be a predictable withdrawal effect.

Two Ways to Come Off

Option 1 — Stop entirely

Stopping without replacement requires a plan for weight, symptoms and any diabetes treatment. Tirzepatide withdrawal data show that regain can occur despite continued lifestyle support; they do not mean lifestyle “failed” or that every person regains the same amount.

No validated retatrutide taper has been shown to prevent regain. Follow the study team’s instructions, especially when stopping because of an adverse event.

Option 2 — Transition to a maintenance agent

A clinician may consider an approved treatment after trial participation, based on eligibility and clinical need. There is no established retatrutide-to-other-drug dose conversion, and continuing tirzepatide in SURMOUNT-4 did not test switching from retatrutide to a lower dose of another medicine.

See switching to retatrutide for the opposite direction and its evidence limits.

Frequently Asked Questions

Will I gain the weight back if I stop retatrutide?

Regain is a reasonable concern, but a retatrutide-specific percentage is unknown. In SURMOUNT-4, people switched from tirzepatide to placebo gained 14.0% from their week 36 weight over the following 52 weeks. Those are tirzepatide results, not a minimum rebound forecast for retatrutide.

Should you cycle retatrutide — stop once you hit your goal weight, then maintain on lifestyle?

No trial result establishes a retatrutide cycling strategy that preserves weight loss. Tirzepatide withdrawal evidence supports planning for possible regain, but does not measure repeated retatrutide cycles. Discuss a long-term plan with the trial team or clinician.

How long does retatrutide stay in your system after the last dose?

Its approximate six-day half-life means exposure declines gradually over several weeks. Five half-lives is a pharmacokinetic estimate, not proof of complete elimination or a timetable for symptom resolution.

Do I need to taper off retatrutide?

There is no validated retatrutide taper proven to prevent weight regain. The reason for stopping and the trial protocol matter. Ask the study team rather than adopting an online taper schedule.

Should I switch to a maintenance medication instead of stopping?

That is an individualized clinical decision. SURMOUNT-4 supports continuing tirzepatide in its studied setting; it did not test switching from retatrutide to another medicine. No dose equivalence has been established.

Is there any retatrutide-specific data on stopping?

We found no completed withdrawal study that establishes a regain rate. TRIUMPH-6 is designed to study maintenance of weight reduction; an ongoing study is not a result.

For on-treatment adverse events (as opposed to stop/regain symptoms), see Retatrutide side effects & safety.

Sources

  • Eli Lilly. Retatrutide development program at ADA 2026.
  • Aronne, L.J., et al. (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA, 331(1), 38–48. Full text.
  • Jastreboff, A.M., et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine, 389, 514–526. DOI: 10.1056/NEJMoa2301972.

Questions to ask your doctor

  • Given my health history, is a GLP-1 medication appropriate for me at all?
  • Which approved option (e.g. semaglutide, tirzepatide) best fits my goals?
  • What starting dose and titration pace would you use, and why?
  • What side effects should I watch for, and when should I call you?
  • How will we monitor whether it's working and when to adjust?

How we keep this honest
What this is
Educational information, not medical advice. It reports published research — it doesn’t recommend that you use, obtain, or supply anything.
Regulatory status
Retatrutide and similar peptides are investigational — not approved by the FDA or any regulator. Semaglutide and tirzepatide are prescription-only medicines, available only through a licensed prescriber.
Our standard
Every claim traces to a primary source. We label the strength of evidence and flag estimates as estimates — never as clinical fact.
No commercial ties
We don’t sell, supply, or link to suppliers of any medicine, and aren’t affiliated with any manufacturer.

Do not make decisions about your health without consulting a qualified healthcare provider. For trial enrolment, see ClinicalTrials.gov. More on how we review.

Grounded in primary sources
NEJMThe LancetJAMAFDAClinicalTrials.gov

Keep exploring

Explore all guides topics →